After Slow Start, St. Jude Says Portico TAVI Is Primed To Gain Traction
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical’s Portico transcatheter aortic valve is poised to become more competitive in Europe in 2014 as more sizes become available, executives told investors during the firm’s Feb. 7 annual investor conference. And the firm is talking to FDA about alternative pivotal trial designs.
You may also be interested in...
St. Jude Halts Portico TAVR Implants Based On IDE Study Imaging Data
The firm says it is temporarily halting implants of its transcatheter aortic health valve replacement worldwide while it reviews CT data showing reduced valve leaflet mobility in some patients treated as part of St. Jude’s U.S. pivotal trial.
New Product Briefs: St. Jude TAVR Update; ADHD, GI Tests Launch
St. Jude expects to receive a CE mark for a transfemoral 25 millimeter version of its Portico transcatheter aortic valve replacement system during the fourth quarter. NEBA Health launches ADHD test. Exalenz BioScience launches test for H. pylori stomach bacteria.
Transcatheter Valves At The Tipping Point
Although Edwards is the pioneer and market leader in TAVR, there is no shortage of competitors – in both the aortic and mitral valve segments – developing next-generation devices who would be happy with a fraction of this potential multibillion-dollar opportunity.